Plasma cathelicidin and longitudinal lung function in current and former smokers

Robert M. Burkes, Jacquie Astemborski, Allison A. Lambert, Todd T Brown, Robert A Wise, Gregory D Kirk, M. Bradley Drummond

Research output: Contribution to journalArticle

Abstract

Introduction Cathelicidin (also known as LL-37 in humans) is an antimicrobial peptide secreted by epithelial and immune cells and regulated by vitamin D. The immunological roles of cathelicidin make it a putative biomarker to identify individuals at risk for reduced lung function. The objective of this study is to determine potential independent associations between low plasma cathelicidin and longitudinal lung function in current or former smokers without COPD. Methods In a nested analysis of 308 participants from an observational cohort study, plasma cathelicidin and serum 25-hydroxy-vitamin D measurements were obtained at baseline, years three and five. The independent association between lowest quartile cathelicidin (<35 ng/ ml) and forced-expiratory-volume-in-1-second (FEV1) at baseline, six and 18 months from each cathelicidin measurement was assessed with generalized estimating equations after adjusting for age, sex, race, smoking status and intensity. The long-term stability of cathelicidin and relationship with vitamin D was evaluated. Results The cohort was 91% African-American, mean age 48.6 years, 32% female, and 81% current smokers. Participants with low cathelicidin were more likely to be female and have lower FEV1. Low cathelicidin was not independently associated with baseline FEV1. There was an independent association between low cathelicidin and reduced FEV1 at six months [-72 ml (95% CI, -140 to -8ml); p = 0.027] and 18 months [-103 ml (95% CI, -180 to -27 ml); p = 0.007]. Cathelicidin was stable over time and not correlated with vitamin D level. Conclusion In current and former smokers with preserved lung function, low cathelicidin is associated with sustained lung function reductions at six and 18 months, suggesting that cathelicidin may be an informative biomarker to predict persistent lung function disparities among at-risk individuals.

Original languageEnglish (US)
Article numbere0212628
JournalPloS one
Volume14
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

lung function
vitamin D
Plasmas
Lung
risk groups
Forced Expiratory Volume
biomarkers
Vitamin D
antimicrobial peptides
African Americans
cohort studies
Biomarkers
CAP18 lipopolysaccharide-binding protein
gender
Association reactions
Chronic Obstructive Pulmonary Disease
cells
Observational Studies
Cohort Studies
Smoking

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Plasma cathelicidin and longitudinal lung function in current and former smokers. / Burkes, Robert M.; Astemborski, Jacquie; Lambert, Allison A.; Brown, Todd T; Wise, Robert A; Kirk, Gregory D; Drummond, M. Bradley.

In: PloS one, Vol. 14, No. 2, e0212628, 01.02.2019.

Research output: Contribution to journalArticle

Burkes, Robert M. ; Astemborski, Jacquie ; Lambert, Allison A. ; Brown, Todd T ; Wise, Robert A ; Kirk, Gregory D ; Drummond, M. Bradley. / Plasma cathelicidin and longitudinal lung function in current and former smokers. In: PloS one. 2019 ; Vol. 14, No. 2.
@article{0df352c5e89b449ba1621c33764699c7,
title = "Plasma cathelicidin and longitudinal lung function in current and former smokers",
abstract = "Introduction Cathelicidin (also known as LL-37 in humans) is an antimicrobial peptide secreted by epithelial and immune cells and regulated by vitamin D. The immunological roles of cathelicidin make it a putative biomarker to identify individuals at risk for reduced lung function. The objective of this study is to determine potential independent associations between low plasma cathelicidin and longitudinal lung function in current or former smokers without COPD. Methods In a nested analysis of 308 participants from an observational cohort study, plasma cathelicidin and serum 25-hydroxy-vitamin D measurements were obtained at baseline, years three and five. The independent association between lowest quartile cathelicidin (<35 ng/ ml) and forced-expiratory-volume-in-1-second (FEV1) at baseline, six and 18 months from each cathelicidin measurement was assessed with generalized estimating equations after adjusting for age, sex, race, smoking status and intensity. The long-term stability of cathelicidin and relationship with vitamin D was evaluated. Results The cohort was 91{\%} African-American, mean age 48.6 years, 32{\%} female, and 81{\%} current smokers. Participants with low cathelicidin were more likely to be female and have lower FEV1. Low cathelicidin was not independently associated with baseline FEV1. There was an independent association between low cathelicidin and reduced FEV1 at six months [-72 ml (95{\%} CI, -140 to -8ml); p = 0.027] and 18 months [-103 ml (95{\%} CI, -180 to -27 ml); p = 0.007]. Cathelicidin was stable over time and not correlated with vitamin D level. Conclusion In current and former smokers with preserved lung function, low cathelicidin is associated with sustained lung function reductions at six and 18 months, suggesting that cathelicidin may be an informative biomarker to predict persistent lung function disparities among at-risk individuals.",
author = "Burkes, {Robert M.} and Jacquie Astemborski and Lambert, {Allison A.} and Brown, {Todd T} and Wise, {Robert A} and Kirk, {Gregory D} and Drummond, {M. Bradley}",
year = "2019",
month = "2",
day = "1",
doi = "10.1371/journal.pone.0212628",
language = "English (US)",
volume = "14",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - Plasma cathelicidin and longitudinal lung function in current and former smokers

AU - Burkes, Robert M.

AU - Astemborski, Jacquie

AU - Lambert, Allison A.

AU - Brown, Todd T

AU - Wise, Robert A

AU - Kirk, Gregory D

AU - Drummond, M. Bradley

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Introduction Cathelicidin (also known as LL-37 in humans) is an antimicrobial peptide secreted by epithelial and immune cells and regulated by vitamin D. The immunological roles of cathelicidin make it a putative biomarker to identify individuals at risk for reduced lung function. The objective of this study is to determine potential independent associations between low plasma cathelicidin and longitudinal lung function in current or former smokers without COPD. Methods In a nested analysis of 308 participants from an observational cohort study, plasma cathelicidin and serum 25-hydroxy-vitamin D measurements were obtained at baseline, years three and five. The independent association between lowest quartile cathelicidin (<35 ng/ ml) and forced-expiratory-volume-in-1-second (FEV1) at baseline, six and 18 months from each cathelicidin measurement was assessed with generalized estimating equations after adjusting for age, sex, race, smoking status and intensity. The long-term stability of cathelicidin and relationship with vitamin D was evaluated. Results The cohort was 91% African-American, mean age 48.6 years, 32% female, and 81% current smokers. Participants with low cathelicidin were more likely to be female and have lower FEV1. Low cathelicidin was not independently associated with baseline FEV1. There was an independent association between low cathelicidin and reduced FEV1 at six months [-72 ml (95% CI, -140 to -8ml); p = 0.027] and 18 months [-103 ml (95% CI, -180 to -27 ml); p = 0.007]. Cathelicidin was stable over time and not correlated with vitamin D level. Conclusion In current and former smokers with preserved lung function, low cathelicidin is associated with sustained lung function reductions at six and 18 months, suggesting that cathelicidin may be an informative biomarker to predict persistent lung function disparities among at-risk individuals.

AB - Introduction Cathelicidin (also known as LL-37 in humans) is an antimicrobial peptide secreted by epithelial and immune cells and regulated by vitamin D. The immunological roles of cathelicidin make it a putative biomarker to identify individuals at risk for reduced lung function. The objective of this study is to determine potential independent associations between low plasma cathelicidin and longitudinal lung function in current or former smokers without COPD. Methods In a nested analysis of 308 participants from an observational cohort study, plasma cathelicidin and serum 25-hydroxy-vitamin D measurements were obtained at baseline, years three and five. The independent association between lowest quartile cathelicidin (<35 ng/ ml) and forced-expiratory-volume-in-1-second (FEV1) at baseline, six and 18 months from each cathelicidin measurement was assessed with generalized estimating equations after adjusting for age, sex, race, smoking status and intensity. The long-term stability of cathelicidin and relationship with vitamin D was evaluated. Results The cohort was 91% African-American, mean age 48.6 years, 32% female, and 81% current smokers. Participants with low cathelicidin were more likely to be female and have lower FEV1. Low cathelicidin was not independently associated with baseline FEV1. There was an independent association between low cathelicidin and reduced FEV1 at six months [-72 ml (95% CI, -140 to -8ml); p = 0.027] and 18 months [-103 ml (95% CI, -180 to -27 ml); p = 0.007]. Cathelicidin was stable over time and not correlated with vitamin D level. Conclusion In current and former smokers with preserved lung function, low cathelicidin is associated with sustained lung function reductions at six and 18 months, suggesting that cathelicidin may be an informative biomarker to predict persistent lung function disparities among at-risk individuals.

UR - http://www.scopus.com/inward/record.url?scp=85062170663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062170663&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0212628

DO - 10.1371/journal.pone.0212628

M3 - Article

VL - 14

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e0212628

ER -